Aurigene Pharmaceutical Services Signs Long-Term Manufacturing Agreement with Global Pharma Major

NEW DELHI: Aurigene Pharmaceutical Services Ltd, a wholly owned subsidiary of Dr. Reddy's Laboratories, has signed a long-term Manufacturing and Supply Agreement (MSA) with a leading global pharmaceutical company. Under the terms of the agreement, Aurigene will handle commercial drug-product manufacturing and supply for a diversified portfolio destined for the USA, Europe, Canada, and emerging markets.

Due to confidentiality obligations under the agreement, the name of the counterparty has not been disclosed. The partnership establishes a comprehensive framework covering technical transfer, process development, scale-up, validation, commercial manufacturing, and long-term supply operations.

The initial product portfolio comprises more than 20 products spanning sterile injectables, biologics, and topicals. These products will be manufactured across the company's facilities located in India.

Commenting on the development, Akhil Ravi, Chief Executive Officer of Aurigene Pharmaceutical Services, stated in a release that the partnership reflects the confidence global innovators place in the company's integrated drug-product development and manufacturing capabilities across sterile injectables, biologics, and topicals.

The partnership is structured to progress through a phased technology transfer program over the next two to three years, which will pave the way for subsequent commercial manufacturing and supply.

At full commercialisation, the portfolio is expected to represent an estimated annual volume of approximately 18 million units, with injectables making up a large portion of the volume. According to the release, revenues from this partnership are expected to commence from the calendar year 2028.

"Long-term manufacturing and supply agreements of this scale highlight the growing reliance of global pharmaceutical companies on Indian manufacturing capabilities. For established players and their subsidiaries, securing multi-year contracts with defined volume trajectories—such as the projected 18 million units expected here—provides structural revenue visibility over a multi-year horizon. However, execution success will depend heavily on navigating the phased technology transfer smoothly and meeting stringent regulatory standards across multiple international markets over the coming years." — Dr. Shishir Gupta, Founder & CEO, StartupLanes